Biological Significance of Proliferation, Apoptosis, Cytokines, and Monocyte/macrophage Cells in Bone Marrow Biopsies of 145 Patients with Myelodysplastic Syndrome

Overview

Journal Int J Hematol

Specialty Hematology

Date 2002 May 10

PMID 11999358

Citations 36

Authors

Krishnan Allampallam

Vilasini Shetty

Suneel Mundle

Diya Dutt

Howard Kravitz

Poluru L Reddy

Sairah Alvi

Naomi Galili

Gurveen S Saberwal

Shalini Anthwal

Maliha W Shaikh

Aaron York

Azra Raza

Affiliations

Soon will be listed here.

Abstract

Labeling index (LI), apoptosis, levels of 2 pro-apoptotic cytokines tumor necrosis factor-alpha (TNF-alpha) and transforming growth factor-beta(TGF-beta), and the number of monocyte/macrophage cells that are the likely source of the cytokines were simultaneously measured in plastic-embedded bone marrow (BM) biopsy sections of 145 patients with myelodysplastic syndromes (MDS). TNF-alpha was correlated with TGF-beta (P = .001) and with monocyte/macrophage cells (P = .003). Patients with excess blasts in their marrows had a higher TGF-beta level (P = .01) and monocyte/macrophage number (P = .05). In a linear regression model,TGF-beta emerged as the most significant biological difference between patients who have excess of blasts and those who do not (P = .01). We conclude that in addition to TNF-alpha, TGF-beta also plays a significant role in the initiation and pathogenesis of MDS, and that a more precise definition of its role will likely identify better preventive and therapeutic strategies.

Citing Articles

Immune-monitoring of myelodysplastic neoplasms: Recommendations from the i4MDS consortium.

Tentori C, Zhao L, Tinterri B, Strange K, Zoldan K, Dimopoulos K Hemasphere. 2024; 8(5):e64.

PMID: 38756352 PMC: 11096644. DOI: 10.1002/hem3.64.

p53 biology and reactivation for improved therapy in MDS and AML.

Zawacka J Biomark Res. 2024; 12(1):34.

PMID: 38481290 PMC: 10936007. DOI: 10.1186/s40364-024-00579-9.

Diagnosis of Myelodysplastic Syndromes: From Immunological Observations to Clinical Applications.

Simoni Y, Chapuis N Diagnostics (Basel). 2022; 12(7).

PMID: 35885563 PMC: 9324119. DOI: 10.3390/diagnostics12071659.

Stem Cells in the Myelodysplastic Syndromes.

Zhan D, Park C Front Aging. 2022; 2:719010.

PMID: 35822030 PMC: 9261372. DOI: 10.3389/fragi.2021.719010.

Immunodepletion of MDSC by AMV564, a novel bivalent, bispecific CD33/CD3 T cell engager, ex vivo in MDS and melanoma.

Cheng P, Chen X, Dalton R, Calescibetta A, So T, Gilvary D Mol Ther. 2022; 30(6):2315-2326.

PMID: 35150889 PMC: 9171150. DOI: 10.1016/j.ymthe.2022.02.005.

References

Mundle S, Venugopal P, Cartlidge J, Pandav D, Gezer S, Robin E . Indication of an involvement of interleukin-1 beta converting enzyme-like protease in intramedullary apoptotic cell death in the bone marrow of patients with myelodysplastic syndromes. Blood. 1996; 88(7):2640-7. View

Papadaki H, Giouremou K, Eliopoulos G . Low frequency of myeloid progenitor cells in chronic idiopathic neutropenia of adults may be related to increased production of TGF-beta1 by bone marrow stromal cells. Eur J Haematol. 1999; 63(3):154-62. DOI: 10.1111/j.1600-0609.1999.tb01763.x. View

Gersuk G, Beckham C, Loken M, Kiener P, Anderson J, FARRAND A . A role for tumour necrosis factor-alpha, Fas and Fas-Ligand in marrow failure associated with myelodysplastic syndrome. Br J Haematol. 1998; 103(1):176-88. DOI: 10.1046/j.1365-2141.1998.00933.x. View

Peddie C, Wolf C, McLellan L, Collins A, Bowen D . Oxidative DNA damage in CD34+ myelodysplastic cells is associated with intracellular redox changes and elevated plasma tumour necrosis factor-alpha concentration. Br J Haematol. 1997; 99(3):625-31. DOI: 10.1046/j.1365-2141.1997.4373247.x. View

San Miguel J, Sanz G, Vallespi T, Del Canizo M, Sanz M . Myelodysplastic syndromes. Crit Rev Oncol Hematol. 1996; 23(1):57-93. DOI: 10.1016/1040-8428(96)00197-7. View

Herold M, Schmalzl F, Zwierzina H . Increased serum interleukin 6 levels in patients with myelodysplastic syndromes. Leuk Res. 1992; 16(6-7):585-8. DOI: 10.1016/0145-2126(92)90006-s. View

Mundle S, Mativi B, Bagai K, Feldman G, Cheema P, Gautam U . Spontaneous down-regulation of Fas-associated phosphatase-1 may contribute to excessive apoptosis in myelodysplastic marrows. Int J Hematol. 1999; 70(2):83-90. View

Raza A, Yousuf N, Bokhari S, Abbas A, Lampkin B, Pancoast J . Cell-cycle characteristics - alterable determinants of remission duration in a study of 179 standard risk newly diagnosed patients with acute myeloid-leukemia. Int J Oncol. 2011; 2(2):301-7. DOI: 10.3892/ijo.2.2.301. View

Allampallam K, Shetty V, Hussaini S, Mazzoran L, Zorat F, Huang R . Measurement of mRNA expression for a variety of cytokines and its receptors in bone marrows of patients with myelodysplastic syndromes. Anticancer Res. 2000; 19(6B):5323-8. View

10.

Raza A . Anti-TNF therapies in rheumatoid arthritis, Crohn's disease, sepsis, and myelodysplastic syndromes. Microsc Res Tech. 2000; 50(3):229-35. DOI: 10.1002/1097-0029(20000801)50:3<229::AID-JEMT6>3.0.CO;2-H. View

11.

Molnar L, Berki T, Hussain A, Nemeth P, Losonczy H . Detection of TNFalpha expression in the bone marrow and determination of TNFalpha production of peripheral blood mononuclear cells in myelodysplastic syndrome. Pathol Oncol Res. 2000; 6(1):18-23. DOI: 10.1007/BF03032653. View

12.

Raza A, Alvi S, Showel M, Cartlidge J, Mundle S, Shetty V . Cell cycle kinetic studies in 68 patients with myelodysplastic syndromes following intravenous iodo- and/or bromodeoxyuridine. Exp Hematol. 1997; 25(6):530-5. View

13.

Vindevoghel L, Lechleider R, Kon A, de Caestecker M, Uitto J, Roberts A . SMAD3/4-dependent transcriptional activation of the human type VII collagen gene (COL7A1) promoter by transforming growth factor beta. Proc Natl Acad Sci U S A. 1998; 95(25):14769-74. PMC: 24524. DOI: 10.1073/pnas.95.25.14769. View

14.

Raza A, Gezer S, Mundle S, Gao X, Alvi S, BOROK R . Apoptosis in bone marrow biopsy samples involving stromal and hematopoietic cells in 50 patients with myelodysplastic syndromes. Blood. 1995; 86(1):268-76. View

15.

Parcharidou A, Raza A, Economopoulos T, Papageorgiou E, Anagnostou D, Papadaki T . Extensive apoptosis of bone marrow cells as evaluated by the in situ end-labelling (ISEL) technique may be the basis for ineffective haematopoiesis in patients with myelodysplastic syndromes. Eur J Haematol. 1999; 62(1):19-26. DOI: 10.1111/j.1600-0609.1999.tb01109.x. View

16.

Shetty V, Hussaini S, Allampallam K, Mundle S, BOROK R, Broderick E . Intramedullary apoptosis of hematopoietic cells in myelodysplastic syndrome patients can be massive: apoptotic cells recovered from high-density fraction of bone marrow aspirates. Blood. 2000; 96(4):1388-92. View

17.

Raza A, Qawi H, Andric T, Dar S, Lisak L, Venugopal P . Pentoxifylline, Ciprofloxacin and Dexamethasone Improve the Ineffective Hematopoiesis in Myelodysplastic Syndrome Patients; Malignancy. Hematology. 2001; 5(4):275-284. DOI: 10.1080/10245332.2000.11746517. View

18.

Kitagawa M, Yamaguchi S, Takahashi M, Tanizawa T, Hirokawa K, Kamiyama R . Localization of Fas and Fas ligand in bone marrow cells demonstrating myelodysplasia. Leukemia. 1998; 12(4):486-92. DOI: 10.1038/sj.leu.2400980. View

19.

Parker J, Mufti G, Rasool F, Mijovic A, Devereux S, Pagliuca A . The role of apoptosis, proliferation, and the Bcl-2-related proteins in the myelodysplastic syndromes and acute myeloid leukemia secondary to MDS. Blood. 2000; 96(12):3932-8. View

20.

Dar S, Mundle S, Andric T, Qawi H, Shetty V, Reza S . Biological characteristics of myelodysplastic syndrome patients who demonstrated high versus no intramedullary apoptosis. Eur J Haematol. 1999; 62(2):90-4. DOI: 10.1111/j.1600-0609.1999.tb01727.x. View